An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

Abstract Background Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for pa...

Descrición completa

Detalles Bibliográficos

Principais autores:	Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswamy
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-10-01
Series:	Pilot and Feasibility Studies
Assuntos:	Microdosing Lysergic acid diethylamide Psychedelics Major depressive disorder
Acceso en liña:	https://doi.org/10.1186/s40814-023-01399-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!